Cargando…
TAK1 regulates hepatic lipid homeostasis through SREBP
Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP reg...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956508/ https://www.ncbi.nlm.nih.gov/pubmed/26973245 http://dx.doi.org/10.1038/onc.2015.453 |
_version_ | 1782444037480906752 |
---|---|
author | Morioka, Sho Sai, Kazuhito Omori, Emily Ikeda, Yuka Matsumoto, Kunihiro Ninomiya-Tsuji, Jun |
author_facet | Morioka, Sho Sai, Kazuhito Omori, Emily Ikeda, Yuka Matsumoto, Kunihiro Ninomiya-Tsuji, Jun |
author_sort | Morioka, Sho |
collection | PubMed |
description | Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through TGF-β activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development. |
format | Online Article Text |
id | pubmed-4956508 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
record_format | MEDLINE/PubMed |
spelling | pubmed-49565082016-09-14 TAK1 regulates hepatic lipid homeostasis through SREBP Morioka, Sho Sai, Kazuhito Omori, Emily Ikeda, Yuka Matsumoto, Kunihiro Ninomiya-Tsuji, Jun Oncogene Article Sterol regulatory element-binding proteins (SREBPs) are key transcription factors regulating cholesterol and fatty acid biosynthesis. SREBP activity is tightly regulated to maintain lipid homeostasis, and is modulated upon extracellular stimuli such as growth factors. While the homeostatic SREBP regulation is well studied, stimuli-dependent regulatory mechanisms are still elusive. Here we demonstrate that SREBPs are regulated by a previously uncharacterized mechanism through TGF-β activated kinase 1 (TAK1), a signaling molecule of inflammation. We found that TAK1 binds to and inhibits mature forms of SREBPs. In an in vivo setting, hepatocyte-specific Tak1 deletion upregulates liver lipid deposition and lipogenic enzymes in the mouse model. Furthermore, hepatic Tak1 deficiency causes steatosis pathologies including elevated blood triglyceride and cholesterol levels, which are established risk factors for the development of hepatocellular carcinoma (HCC) and are indeed correlated with Tak1-deficiency-induced HCC development. Pharmacological inhibition of SREBPs alleviated the steatosis and reduced the expression level of the HCC marker gene in the Tak1-deficient liver. Thus, TAK1 regulation of SREBP critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent HCC development. 2016-03-14 2016-07-21 /pmc/articles/PMC4956508/ /pubmed/26973245 http://dx.doi.org/10.1038/onc.2015.453 Text en http://www.nature.com/authors/editorial_policies/license.html#terms Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Morioka, Sho Sai, Kazuhito Omori, Emily Ikeda, Yuka Matsumoto, Kunihiro Ninomiya-Tsuji, Jun TAK1 regulates hepatic lipid homeostasis through SREBP |
title | TAK1 regulates hepatic lipid homeostasis through SREBP |
title_full | TAK1 regulates hepatic lipid homeostasis through SREBP |
title_fullStr | TAK1 regulates hepatic lipid homeostasis through SREBP |
title_full_unstemmed | TAK1 regulates hepatic lipid homeostasis through SREBP |
title_short | TAK1 regulates hepatic lipid homeostasis through SREBP |
title_sort | tak1 regulates hepatic lipid homeostasis through srebp |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956508/ https://www.ncbi.nlm.nih.gov/pubmed/26973245 http://dx.doi.org/10.1038/onc.2015.453 |
work_keys_str_mv | AT moriokasho tak1regulateshepaticlipidhomeostasisthroughsrebp AT saikazuhito tak1regulateshepaticlipidhomeostasisthroughsrebp AT omoriemily tak1regulateshepaticlipidhomeostasisthroughsrebp AT ikedayuka tak1regulateshepaticlipidhomeostasisthroughsrebp AT matsumotokunihiro tak1regulateshepaticlipidhomeostasisthroughsrebp AT ninomiyatsujijun tak1regulateshepaticlipidhomeostasisthroughsrebp |